Evidence map›Paper›PMID 32555990›Full record

Trial reportArchives of endocrinology and metabolism

Intrathyroid injection of dexamethasone inhibits Th2 cells in Graves' disease.

Ke He, Peng Jiang, Bing-Li Liu, Xiao-Mei Liu, Xiao-Ming Mao, Yun Hu

Open access · diamondAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Archives of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.9field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. The role of autophagy in Graves disease: knowns and unknowns.Frontiers in cell and developmental biology · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Ke HeDepartment of Endocrinology, Wuxi Hospital of Traditional Chinese Medicine, Wuxi Hospital Affiliated to Nanjing University of Chinese Medicine, Wuxi, China.ORCID http://orcid.org/0000-0002-6077-3713
Peng JiangDepartment of Thyroid and Breast Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID http://orcid.org/0000-0003-4200-3616
Bing-Li LiuDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID http://orcid.org/0000-0002-9682-3612
Xiao-Mei LiuDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID http://orcid.org/0000-0003-1070-7133
Xiao-Ming MaoDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID http://orcid.org/0000-0001-7485-5245
Yun HuDepartment of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China.ORCID http://orcid.org/0000-0002-4477-3641
Nanjing Medical University · CNNanjing University of Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveIntrathyroid injection of dexamethasone (IID) was used for decrease the relapse rate of hyperthyroidism in the treatment of Graves' disease (GD), but the mechanism is still unclear. We aimed to explore the effect of IID on T help (Th)1/Th2 cells and their chemokine in patients with GD. SUBJECTS AND

methodsA total of 42 patients with GD who were euthyroidism by methimazole were randomly divided into IID group (n = 20) and control group (n = 22). Thyroid function and associated antibody, Th1/Th2 cells proportion, serum CXCL10 and CCL2 levels, and CXCR3/CCR2 mRNA expression in peripheral blood mononuclear cells before and after 3-month IID treatment were tested by chemiluminescence assay, Flow cytometry, ELISA, and real-time PCR, respectively. Thyroid follicular cells were stimulated by IFN-γ and TNF-α and treated with dexamethasone in vitro. CXCL10 and CCL2 levels in supernatant were determined.

resultsAfter 3-month therapy, the proportion of Th2 cells and serum CCL2 levels, as well as TPOAb, TRAb levels and thyroid volume decreased in IID group (p < 0.05). However, the proportion of Th1 and CXCL10 levels had no change in IID group and control (p > 0.05). The CXCR3/CCR2 ratio had no change in both groups (p > 0.05).

conclusionIID therapy could inhibit peripheral Th2 cells via decreasing CCL2 level in peripheral blood, and this result partly explain the effects of IID therapy on prevention of relapse of GD. Arch Endocrinol Metab. 2020;64(3):243-50.

Indexed as

AdultAnti-Inflammatory AgentsDexamethasoneFemaleGraves DiseaseHumansMaleMiddle AgedRecurrenceSecondary PreventionTh1 CellsTh2 CellsTreatment OutcomeAnti-Inflammatory AgentsDexamethasone

Identifiers

PMID32555990
PMCPMC10522220
OpenAlexW3036104064

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.